-
Featured Authors
-
Archives
- February 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- May 2014
- April 2014
- March 2014
- February 2014
- January 2014
- December 2013
- November 2013
- October 2013
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Tag Archives: biotech regulatory issues
“When Genetic Engineering Came Of Age”
October 29 was the 30th anniversary of the approval by the Food and Drug Administration (FDA) of human insulin synthesized in genetically engineered bacteria. In an article for Forbes, Henry Miller, the founding director of the FDA’s Office of Biotechnology, marked the anniversary and commented on today’s regulatory environment: “Regulators have adopted a highly risk-averse and even adversarial mindset, few new drugs are approved without convening extramural advisory committees, and decisions are sometimes hijacked by Read More >
How to Become a Global Biotech Leader: Innovation and the Worldview Report
What are the BRICS of the future? Latin America, Korea, North Africa, Thailand, Turkey? Scientific American’s 2012 Worldview contains a special section on Emerging Markets 2.0 and an exploration of countries that are showing promise for future development and an on-the-ground look at some of the science parks, incubators, research centers, or other hot spots of innovation that are coming into their own. With the release of Worldview Report and Scorecard at the 2012 BIO Read More >
People With Rare Diseases Face a Host of Unique Challenges
By Dennis Jackman, Senior Vice President, Public Affairs, CSL Behring People with rare and serious medical disorders encounter a host of unique challenges–from obtaining a correct diagnosis, to identifying an appropriate course of treatment and gaining affordable access to the care they need. They and their families, caretakers and health care providers face a constant struggle to identify and access available resources, away from the attention of traditional media that focuses on more common disorders Read More >
How to grow the economy and feed the world
By Barbara Wells, President and CEO, ArborGen Chair, BIO Food and Agriculture Section Governing Board For the past two decades, the United States has led the world in crop biotechnology innovation. Under this leadership, American growers have produced most of the world’s food, fiber and energy, while the U.S. agricultural sector experienced sustained economic growth and a positive trade balance. But an increasingly complicated regulatory system and threats of litigation from opponents of technology have Read More >
Biologics & Biosimilars: What is the Science Telling Us?
Panelists from the varied backgrounds of academia, business and regulation agreed on the highest scientific standards of biosimilar regulation. Each panelist emphasized the need for the most stringent of standards in order to ensure patient safety and efficacy within the emerging biosimilars market. As Brian Liang, Executive Director of the Institute of Health Law Studies at California Western School of Law, summed it up, “the need in biosimilars is to focus on science, not cost. These are Read More >
